The agreement grants Dr Reddy's the exclusive right to distribute Briviact in India, the Hyderabad-based company said in a filing to BSE.
"In our endeavour to make innovative medicines accessible to patients in India, we are excited to partner with UCB India for Briviact, a novel treatment for epilepsy that will make a difference to the lives of patients living with epilepsy," Dr Reddy's Branded Markets (India and Emerging Markets) CEO MV Ramana said.
"This partnership is another important step towards us providing value together to patients by making Briviact available as an additional treatment choice for epilepsy," UCB Neurology Patient Value Unit Head of International Markets Max Bricchi said.
Shares of Dr Reddy's Laboratories today closed at Rs 2,329.80 per scrip on BSE, up 2.80 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)